Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Prestige Consumer Healthcare's 1-Year ROIIC % for the quarter that ended in Jun. 2026 was -3.79%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Prestige Consumer Healthcare 1-Year ROIIC % Related Terms
Prestige Consumer Healthcare 1-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PBV vs BCRX, AMLX, SUPN: 1-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare 1-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's 1-Year ROIIC % falls into.
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( 183.5416 (Jun. 2026) - 235.5842 (Jun. 2025) )
/
( 3781.907 (Jun. 2026) - 2771.674 (Jun. 2025) )
=
-52.0426
/
1010.233
=
-5.15%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Prestige Consumer Healthcare (FRA:PBV) has a 1-Year ROIIC % of -3.79 as of Jun. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Prestige Consumer Healthcare and its competitors. According to the industry distribution chart, Prestige Consumer Healthcare ranks #524 out of 890 companies in the Drug Manufacturers industry, placing it in the top 58.9%.
Is Prestige Consumer Healthcare's 1-Year ROIIC % too high?
Prestige Consumer Healthcare's current 1-Year ROIIC % is -3.79. Based on the distribution chart, Prestige Consumer Healthcare ranks #524 out of 890 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Prestige Consumer Healthcare has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's 1-Year ROIIC % compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #524 out of 890 companies for 1-Year ROIIC %. This places Prestige Consumer Healthcare in the lower half of its industry. The industry median 1-Year ROIIC % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Drug Manufacturers company?
The median 1-Year ROIIC % among Drug Manufacturers companies is 1.51, based on 890 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median 1-Year ROIIC % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current 1-Year ROIIC % is -3.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (FRA:PBV) is currently considered Modestly Undervalued. The stock's GF Value™ is €59.76, compared to a current price of €43.80 — trading 26.7% below its estimated fair value. The current 1-Year ROIIC % is -3.79. Prestige Consumer Healthcare's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Prestige Consumer Healthcare (FRA:PBV), the current 1-Year ROIIC % is -3.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (FRA:PBV) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of €43.80 is trading 26.7% below its estimated GF Value™ of €59.76.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for FRA:PBV:
1-Year ROIIC %: -3.79
GF Value™: €59.76 vs. price of €43.80 (26.7% below fair value)
No single metric tells the full story. See the FRA:PBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
72GF Score
Get the complete analysis for FRA:PBV
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PBV has been successfully added to your 
